Literature DB >> 15674360

BCR/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR/ABL-positive cells.

M Jongen-Lavrencic1, S Salesse, R Delwel, C M Verfaillie.   

Abstract

The mechanism underlying p210(BCR/ABL) oncoprotein-mediated transformation in chronic myelogenous leukemia (CML) is not fully understood. We hypothesized that p210(BCR/ABL) suppresses expression of genes which may explain at least some of the pathogenetic features of CML. A subtractive cDNA library was created between BCR/ABL-enhanced-green-fluorescent-protein (GFP)-transduced umbilical cord blood (UCB) CD34+ cells and GFP-transduced UCB CD34+ cells to identify genes whose expression is downregulated by p210(BCR/ABL). At least 100 genes were identified. We have confirmed for eight of these genes that expression was suppressed by quantitative real-time-RT-PCR (Q-RT-PCR) of additional p210(BCR/ABL)-transduced CD34+ UCB cells as well as primary early chronic phase (CP) bone marrow (BM) CML CD34+ cells. Imatinib mesylate reversed downregulation of some genes, to approximately normal levels. Several of the genes are implicated in cell adhesion and motility, including L-selectin, intercellular adhesion molecule-1 (ICAM-1), and the chemokine receptor, CCR7, consistent with the known defect in adhesion and migration of CML cells. Compared with GFP UCB or normal (NL) BM CD34+ cells, p210 UCB and CML CD34+ cells migrated poorly towards the CCR7 ligands, CCL19 and CCL21, suggesting a possible role for CCR7 in the abnormal migratory behavior of CML CD34+ cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15674360     DOI: 10.1038/sj.leu.2403626

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

Review 1.  C-C Chemokine Receptor 7 in Cancer.

Authors:  Colin A Bill; Christopher M Allen; Charlotte M Vines
Journal:  Cells       Date:  2022-02-14       Impact factor: 6.600

2.  The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia.

Authors:  Stephen D Griffiths; John Burthem; Richard D Unwin; Tessa L Holyoake; Junia V Melo; Guy S Lucas; Anthony D Whetton
Journal:  Mol Biotechnol       Date:  2007-06       Impact factor: 2.695

3.  Evolutionary Dynamics of Chronic Myeloid Leukemia Progression: the Progression-Inhibitory Effect of Imatinib.

Authors:  Robert C Jackson; Tomas Radivoyevitch
Journal:  AAPS J       Date:  2016-03-23       Impact factor: 4.009

Review 4.  Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms.

Authors:  Peter Valent; Irina Sadovnik; Gregor Eisenwort; Harald Herrmann; Karin Bauer; Niklas Mueller; Wolfgang R Sperr; Daniel Wicklein; Udo Schumacher
Journal:  Semin Cancer Biol       Date:  2019-08-10       Impact factor: 15.707

5.  Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia.

Authors:  Keunwook Lee; Ki Taek Nam; Sung Hoon Cho; Prathyusha Gudapati; Yoonha Hwang; Do-Sim Park; Ross Potter; Jin Chen; Emmanuel Volanakis; Mark Boothby
Journal:  J Exp Med       Date:  2012-04-02       Impact factor: 14.307

6.  Extensive gene-specific translational reprogramming in a model of B cell differentiation and Abl-dependent transformation.

Authors:  Jamie G Bates; Julia Salzman; Damon May; Patty B Garcia; Gregory J Hogan; Martin McIntosh; Mark S Schlissel; Pat O Brown
Journal:  PLoS One       Date:  2012-05-31       Impact factor: 3.240

7.  Nanomechanical measurement of adhesion and migration of leukemia cells with phorbol 12-myristate 13-acetate treatment.

Authors:  Zhuo Long Zhou; Jing Ma; Ming-Hui Tong; Barbara Pui Chan; Alice Sze Tsai Wong; Alfonso Hing Wan Ngan
Journal:  Int J Nanomedicine       Date:  2016-12-07

8.  Mtss1 is a critical epigenetically regulated tumor suppressor in CML.

Authors:  M Schemionek; O Herrmann; M M Reher; N Chatain; C Schubert; I G Costa; S Hänzelmann; E G Gusmao; S Kintsler; T Braunschweig; A Hamilton; G V Helgason; M Copland; A Schwab; C Müller-Tidow; S Li; T L Holyoake; T H Brümmendorf; S Koschmieder
Journal:  Leukemia       Date:  2015-12-01       Impact factor: 11.528

9.  Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts.

Authors:  Michele Massimino; Elena Tirrò; Stefania Stella; Livia Manzella; Maria Stella Pennisi; Chiara Romano; Silvia Rita Vitale; Adriana Puma; Cristina Tomarchio; Sandra Di Gregorio; Agostino Antolino; Francesco Di Raimondo; Paolo Vigneri
Journal:  Front Pharmacol       Date:  2021-06-30       Impact factor: 5.810

10.  Laser capture microdissection and cDNA array analysis of endometrium identify CCL16 and CCL21 as epithelial-derived inflammatory mediators associated with endometriosis.

Authors:  Ashwini L Chand; Andrew S Murray; Rebecca L Jones; Natalie J Hannan; Lois A Salamonsen; Luk Rombauts
Journal:  Reprod Biol Endocrinol       Date:  2007-05-17       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.